Money back guarantee
Our billing is certified by:
Sanofi nabs long-sought FDA approval for daily GLP-1 contender Adlyxin - FiercePharma
FiercePharmaSanofi nabs long-sought FDA approval for daily GLP-1 contender AdlyxinFiercePharmaAfter topping its potential rival Bydureon and the DPP-4 blockbuster Januvia in separate trials, semaglutide is set to go to the FDA for approval later this year, with a potential launch in late 2017.
Merck's 2Q16 Estimates: Expected Growth Contributors - Market Realist
Market RealistMerck's 2Q16 Estimates: Expected Growth ContributorsMarket RealistAs discussed earlier, nearly 90% of total 2Q16 revenue for Merck and Co.
Why Investors Can Expect Operational Growth from Merck in 2Q16 - Market Realist
Why Investors Can Expect Operational Growth from Merck in 2Q16Market RealistThese drugs include Januvia, Janumet, Zetia, Vytorin, Remicade, Isentress, Gardasil, Proquad/Varivax, and Cubicin.
Novo's weekly GLP-1 aces two head-to-head trials against Januvia, Bydureon - FiercePharma
FiercePharmaNovo's weekly GLP-1 aces two head-to-head trials against Januvia, BydureonFiercePharmaThe Novo drug beat Januvia by a bigger margin, with reductions in A1C of 1.
Can Keytruda Deliver Earnings Growth For Merck? - Benzinga
BenzingaCan Keytruda Deliver Earnings Growth For Merck?BenzingaMRK might also see a sales boost from Zepatier, which fights hepatitis C, and Januvia, a Type 2 diabetes medication.
Copyright © cheapgenerics24.com